Intranasal Administration with a spray to nose
- Proven animal PoC with the disease model
- Tested with human lung cells in vitro
- Specifically targeting lung and heart which are vulnerable to viral infection
Patient-friendly treatment
- Non-invasive intranasal spray
- Portable and easily applied anytime and anywhere
- Safe and flexible in dose intake
Commercial Potential
- Intranasal therapy for prevention and/or treatment for early to late stages
- Substantially cheaper to produce and administer compared to other treatment drugs (e.g., antiviral antibody drugs)
- No special cold chain distribution system required
- Long shelf life
- Safe for those with pre-existing chronic diseases and elderly
Who We Are
As one of the portfolio drug development companies under Curyx Partners platform, Curyx Partners Therapeutics develops novel intranasal peptide therapeutics against COVID-19. Currently, because there is no treatment for COVID-19 available, developing effective therapeutic agent is of the highest importance at the moment. Furthermore, Curyx Partners Therapeutics has a number of innovative and commercially attractive assets to continue to target other coronavirus-related infectious diseases which, unfortunately, may continue to arise and spread in the future.
Call Us
852-2155-9599
Email Us
info@mstonepartners.com
Our Address
Unit 805, 8/F Mirror Tower,
61 Mody Road,
Tsim Sha Tsui,
Kowloon, Hong Kong
61 Mody Road,
Tsim Sha Tsui,
Kowloon, Hong Kong